Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in India. The decision, spearheaded by CEO David Ricks, is aimed at bolstering the company’s global research efforts and accelerating innovation in critical therapeutic areas such as diabetes, oncology, and immunology.

During a recent briefing, David Ricks highlighted India’s growing significance in the global pharmaceutical landscape, noting the country’s talent pool, infrastructure, and commitment to healthcare innovation. "India plays a pivotal role in our global R&D strategy," said Ricks. "Our expansion here reflects our commitment to tapping into India’s diverse expertise, fostering collaboration, and advancing our mission to discover and develop life-changing medicines."

The research center, located in Bengaluru, has been a crucial hub for Eli Lilly’s work in biopharmaceutical research, data science, and clinical trials. With this expansion, the company aims to double its investment in India over the next few years, creating hundreds of new jobs and enhancing its research capabilities in cutting-edge areas such as AI-driven drug discovery and personalized medicine.

Eli Lilly’s expansion plan also aligns with the Indian government's initiatives to position the country as a global R&D destination. By leveraging local talent and infrastructure, Eli Lilly aims to deepen its footprint in India while contributing to the development of high-quality treatments that will benefit patients worldwide.